Shares of Surmodics, Inc. (NASDAQ:SRDX) have received a consensus rating of “Hold” from the six ratings firms that are presently covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $40.00.

Several research firms have recently issued reports on SRDX. Lake Street Capital began coverage on shares of Surmodics in a research report on Friday, July 14th. They set a “buy” rating and a $40.00 price objective for the company. ValuEngine raised shares of Surmodics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Aegis began coverage on shares of Surmodics in a research report on Tuesday, June 27th. They set a “buy” rating for the company. Finally, BidaskClub raised shares of Surmodics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd.

Shares of Surmodics (NASDAQ SRDX) opened at 31.00 on Friday. Surmodics has a one year low of $21.90 and a one year high of $32.80. The stock has a market cap of $406.38 million, a price-to-earnings ratio of 67.54 and a beta of 0.86. The stock’s 50 day moving average price is $29.84 and its 200 day moving average price is $26.26.

Surmodics (NASDAQ:SRDX) last released its quarterly earnings data on Thursday, August 3rd. The company reported $0.09 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.10. The business had revenue of $17.80 million during the quarter, compared to analysts’ expectations of $15.98 million. Surmodics had a net margin of 8.66% and a return on equity of 7.28%. The company’s revenue for the quarter was down 11.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.37 EPS. Analysts forecast that Surmodics will post $0.31 earnings per share for the current year.

WARNING: “Surmodics, Inc. (SRDX) Receives Average Rating of “Hold” from Analysts” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/20/surmodics-inc-srdx-receives-average-rating-of-hold-from-analysts.html.

In related news, CEO Gary R. Maharaj sold 5,000 shares of the business’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $25.75, for a total value of $128,750.00. Following the completion of the sale, the chief executive officer now directly owns 126,807 shares of the company’s stock, valued at $3,265,280.25. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Joseph J. Stich sold 1,000 shares of the business’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $27.28, for a total transaction of $27,280.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 6,801 shares of company stock valued at $178,338. Corporate insiders own 6.40% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA lifted its position in Surmodics by 66.1% in the second quarter. BNP Paribas Arbitrage SA now owns 4,270 shares of the company’s stock valued at $120,000 after acquiring an additional 1,700 shares during the last quarter. Thrivent Financial For Lutherans purchased a new stake in Surmodics in the second quarter valued at $226,000. Nationwide Fund Advisors lifted its position in Surmodics by 15.8% in the second quarter. Nationwide Fund Advisors now owns 8,427 shares of the company’s stock valued at $237,000 after acquiring an additional 1,149 shares during the last quarter. Texas Permanent School Fund lifted its position in Surmodics by 0.9% in the second quarter. Texas Permanent School Fund now owns 9,693 shares of the company’s stock valued at $273,000 after acquiring an additional 88 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in Surmodics by 2.4% in the second quarter. The Manufacturers Life Insurance Company now owns 11,312 shares of the company’s stock valued at $318,000 after acquiring an additional 262 shares during the last quarter. 84.85% of the stock is owned by hedge funds and other institutional investors.

About Surmodics

Surmodics, Inc is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device.

Receive News & Ratings for Surmodics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.